Drug intelligence / Profile preview

OLX-23010

Development stage: Preclinical
Lead developer: Oligomerix
Modality: Small Molecules
Administration: Oral (preclinical/early Research)

Overview

OLX-23010 is a second-generation small-molecule tau self-association inhibitor developed by Oligomerix for the treatment of dementia. It targets the tau protein, specifically inhibiting its self-association and oligomerization, which are implicated in neurodegenerative diseases such as Alzheimer's disease and other dementias. The drug is classified as an antidementia agent and represents a new molecular entity within this therapeutic area. As of the latest updates, it remains in early research or discovery phases with no clinical trials or regulatory approvals reported[1][2].

Targets

MAPT (Microtubule-associated protein tau)

Beyond the preview

Go deeper on OLX-23010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OLX-23010.

Explore the full profile